Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,235.80 | 60.70 | 0.74% |
| CAC 40 | 7,536.26 | 33.48 | 0.45% |
| DAX 40 | 22,242.45 | 177.94 | 0.81% |
| Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
| FTSE 100 | 8,415.25 | 7.81 | 0.09% |
| HKSE | 21,959.14 | 21.60 | -0.10% |
| NASDAQ | 17,382.94 | 216.90 | 1.26% |
| Nikkei 225 | 35,887.89 | 182.15 | 0.51% |
| NZX 50 Index | 12,121.14 | 103.30 | 0.86% |
| S&P 500 | 5,525.21 | 40.44 | 0.74% |
| S&P/ASX 200 | 8,029.60 | 61.40 | 0.77% |
| SSE Composite Index | 3,295.32 | 0.26 | 0.01% |